# Cancer Therapeutics Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA AT DAVIS · 2021 · $105,929

## Abstract

CANCER THERAPEUTICS PROGRAM (CTP)
PROJECT SUMMARY/ABSTRACT
The Cancer Therapeutics Program (CTP) is one of two clinical research programs of the UC Davis
Comprehensive Cancer Center (UCDCCC). The mission of CTP is to discover new molecular biomarkers and
targets for cancer therapeutics, to accelerate the rate of new agent development, and to translate basic
science and preclinical findings made at UCDCCC into clinical trials to ultimately benefit patients in the
catchment area. CTP is led by Kit Lam, MD, PhD, an expert in drug discovery and development, and Richard
Valicenti, MD, an experienced clinical trialist. Together, they bridge the spectrum of cancer research that
facilitates the integration and translation of basic science discoveries, drug development, and preclinical
research to directly inform human studies and clinical trials. CTP has three Specific Aims: Aim 1 is to develop
and apply new tools for discovery of new biomarkers, therapeutic targets, novel imaging techniques, and lead
compounds. Aim 2 is to develop new anti-neoplastic drugs and innovative drug-delivery modalities. Aim 3 is to
develop and conduct hypothesis-driven clinical trials based on strong preclinical rationale. In the past four
years, CTP investigators have developed novel enabling technologies such as the new intravital microscope
EyePod, novel inhibitors against new targets (e.g., galectin-1), and innovative drug delivery platforms such as
bioengineered RNAs (BERAs) and receptor-mediated transformable peptides. Some of these agents are in the
pre-IND and IND stages. In addition, two clinical trial awards (UM1 and UG1 LAPS) were renewed which fully
integrates CTP investigators into NCI’s clinical trial networks (ETCTN and NCTN). CTP has 41 Full members
from five schools/colleges and 15 diverse academic departments at UC Davis, highlighting the multidisciplinary
nature of the program. As a clinical program, CTP has a mix of MDs (22), PhDs (14), MD/PhDs (5). CTP’s total
cancer relevant funding is $12M annual direct cost, including $7.7M in peer-reviewed funding and $2.1M in
NCI funding. CTP members are highly productive, publishing 739 articles this cycle, of which 31% are intra-
programmatic, 31% inter-programmatic, 50% multi-institutional, and 26% published in high impact journals.

## Key facts

- **NIH application ID:** 10269787
- **Project number:** 2P30CA093373-19
- **Recipient organization:** UNIVERSITY OF CALIFORNIA AT DAVIS
- **Principal Investigator:** KIT S LAM
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $105,929
- **Award type:** 2
- **Project period:** 2002-07-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10269787

## Citation

> US National Institutes of Health, RePORTER application 10269787, Cancer Therapeutics Program (2P30CA093373-19). Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/grant/nih/10269787. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*